Gleevec shows promise in gastrointestinal tumors

Novartis (NVS; SWX:NOVN) reported data from a 36-patient Phase II study of its Gleevec imatinib mesylate to treat unresectable or metastatic gastrointestinal stromal tumors in which 89% of initially s...